Adona Medical Presents Interatrial Shunt Technology for Heart Failure Management

July 10, 2023—Adona Medical, a Shifamed portfolio company announced that its investigational next-generation heart failure management platform was featured at the CSI Frankfurt 2023 conference, which was held from June 28 to July 1, 2023 in Frankfurt am Main, Germany. Adona is a preclinical company that focuses on developing interatrial shunting and hemodynamic monitoring systems for heart failure.

Brian Fahey, cofounder and Chief Executive Officer of Adona Medical, introduced the company’s developing interatrial shunt technology with a presentation during the Focus Heart Failure Interventions session at CSI Frankfurt.

According to the company, the Adona heart failure management platform includes an adjustable interatrial shunt with integrated biatrial pressure monitoring. The shunt flow channel features an adaptable geometry so it can be made larger or smaller at any time post implantation. This aims to allow for the shunting flow or dose to be optimized for patient needs at the time of the initial procedure, and adjusted in the future as the patient’s condition evolves.

Additionally, the integrated sensors are designed to automate the capture of pressure readings from both the left and right atria multiple times a day without requiring patient interaction. These daily readings can provide physicians with a more complete understanding of a patient’s hemodynamic status and can help augment shunt therapy by enabling more informed pharmaceutical management, noted the Adona Medical press release.

Marat Fudim, MD, who served as comoderator of the Focus Heart Failure Interventions session, commented in the company’s press release, “This is a novel device that combines some unique features such as an adjustable shunt mechanism and hemodynamic monitoring. This is very intriguing given the ongoing debate about the right shunt size for individual patients and the ‘booming’ space of remote patient monitoring.” Dr. Fudim is an advanced heart failure specialist and Assistant Professor of Medicine at Duke University in Durham, North Carolina.

Also in the press release, Fahey stated, “Adona Medical is committed to providing heart failure patients and physicians with technologies that address the shortcomings of currently available solutions. You’d struggle to find a physician comfortable with deciding on a fixed dose of medication for a patient and never being able to alter it in the future or monitor its effects, but this is comparable to the use case for interatrial shunts currently under clinical investigation.”

Fahey continued, “At Adona, we believe that patient care can be pushed forward by a customizable and adjustable shunting approach combined with an advanced hemodynamic monitoring solution. We were thrilled to be invited to present at CSI Frankfurt this year to share the progress we’ve made on our heart failure platform.”